Skip to main content
SpringerLink
Log in

Management of risk factors for accelerated atherosclerosis

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Atherosclerosis is a relentlessly progressive process of segmental vessel narrowing or occlusion involving several vascular beds. It accounts for the majority of strokes, which remain a global leading cause of death and long-term disability. The limited options for acute stroke therapy make stroke prevention an important therapeutic approach, particularly in patients who have already experienced stroke.

Given the multifactorial pathogenesis of atherosclerotic disease, an aggressive multimodal preventive strategy is required to mitigate risk of recurrent stroke. Such a strategy would incorporate proven treatments specifically targeting the under lying disease process. A vast number of strokes could be prevented by optimal treatment of modifiable vascular risk factors.

This paper presents current evidence-based management of conventional and novel vascular risk factors in patients with ischemic stroke whose underlying pathophysiologic mechanism is accelerated atherosclerosis. Therapies discussed include antithrombotics, statins, antihypertensives, and surgical/endovascular treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Munger MA, Hawkins DW: Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc 2004, 44:S5–S12.

    Article  Google Scholar 

  2. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126

    Article  CAS  PubMed  Google Scholar 

  3. Sacco RL, Adams R, Albers G, et al.: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006, 37:577–617.

    Article  PubMed  Google Scholar 

  4. Lloyd-Jones D, Adams R, Carnethon M, et al.: Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480–486.

    Article  PubMed  Google Scholar 

  5. Coull A, Lovett JK, Rothwell PM: Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004, 328:326.

    Article  CAS  PubMed  Google Scholar 

  6. Kleindorfer D, Panagos P, Pancioli A, et al.: Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005, 36:720–723.

    Article  PubMed  Google Scholar 

  7. Johnston S, Gress DR, Browner WS, Sidney S: Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000, 284:2901–2906.

    Article  CAS  PubMed  Google Scholar 

  8. Hankey G: Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003, 16(Suppl 1):14–19.

    Article  PubMed  Google Scholar 

  9. Hardie K, Hankey GJ, Jamrozik K, et al.: Ten-year survival after first-ever stroke in the Perth community stroke study. Stroke 2003, 34:1842–1846.

    Article  PubMed  Google Scholar 

  10. Rothwell PM, Giles MF, Chandratheva A, et al.: Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007, 370:1432–1442.

    Article  PubMed  Google Scholar 

  11. Rashid P, Leonardi-Bee J, Bath P: Blood pressure reduction and secondary prevention of stroke and other vascular events: a systemic review. Stroke 2003, 34:2741–2748.

    Article  PubMed  Google Scholar 

  12. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl) 1995, 108:710–717.

  13. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041.

    Article  Google Scholar 

  14. Yusuf S, Diener HC, Sacco RL, et al.: Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225–1237.

    Article  CAS  PubMed  Google Scholar 

  15. Physician’s Desk Reference, edn 57. New York: Thomson Healthcare; 2002.

  16. Rx List. Available at http://www.rxlist.com. Last accessed on September 3, 2009.

  17. Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757–767.

    Article  CAS  Google Scholar 

  18. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549–559.

    Article  Google Scholar 

  19. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71–86.

  20. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329–1339.

    Article  Google Scholar 

  21. Diener HC, Bogousslavsky J, Brass LM, et al.: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebocontrolled trial. Lancet 2004, 364:331–337.

    Article  CAS  PubMed  Google Scholar 

  22. Bhatt DL, Fox KAA, Hacke W, et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706–1717.

    Article  CAS  PubMed  Google Scholar 

  23. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1–13.

    Article  CAS  PubMed  Google Scholar 

  24. ESPRIT Study Group, Halkes PH, van Gijn J, et al.: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 2006, 367:1665–1673.

    Article  CAS  PubMed  Google Scholar 

  25. Sacco RL, Diener HC, Yusuf S, et al.: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238–1251.

    Article  CAS  PubMed  Google Scholar 

  26. The American Diabetes Association: Executive summary: standards of medical care in diabetes—2009. Diabetes Care 2009, 32:S6–S12.

    Article  Google Scholar 

  27. Drexel H, Aczel S, Marte T, et al.: Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005, 28:101–107.

    Article  CAS  PubMed  Google Scholar 

  28. Wilcox R, Bousser MG, Betteridge DJ: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04). Stroke 2007, 38:65–73.

    Article  CAS  Google Scholar 

  29. Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989, 298:789–794.

    Article  CAS  PubMed  Google Scholar 

  30. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med 1991, 325:445–453.

    Article  Google Scholar 

  31. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study: Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995, 273:1421–1428.

    Article  Google Scholar 

  32. Halliday A, Mansfield A, Marro J, et al.: Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. Lancet 2004, 363:1491–1502.

    Article  CAS  PubMed  Google Scholar 

  33. Gray WA, White HJ Jr, Barrett DM, et al.: Carotid stenting and endarterectomy: a clinical and cost comparison of revascularization strategies. Stroke 2002, 33:1063–1070.

    Article  PubMed  Google Scholar 

  34. Nussbaum ES, Heros RC, Erickson DL, et al.: Cost-effectiveness of carotid endarterectomy. Neurosurgery 1996, 38:237–244.

    Article  CAS  PubMed  Google Scholar 

  35. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001, 357:1729–1737.

  36. Yadav JS, Wholey MH, Kuntz RE, et al.: Protected carotidartery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004, 351:1493–1501.

    Article  CAS  PubMed  Google Scholar 

  37. Eckstein HH, Ringleb P, Allenberg JR, et al.: Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenosis at 2 years: a multinational, prospective, randomized trial. Lancet Neurol 2008, 7:893–902.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stroke Center and Department of Neurology, University of California at Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA

    Sarah Song

Authors
  1. Sarah Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce Ovbiagele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Song, S., Ovbiagele, B. Management of risk factors for accelerated atherosclerosis. Curr Treat Options Neurol 11, 460–472 (2009). https://doi.org/10.1007/s11940-009-0050-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0050-4

Keywords

Search

Navigation